0001855763-24-000004.txt : 20240510 0001855763-24-000004.hdr.sgml : 20240510 20240510163446 ACCESSION NUMBER: 0001855763-24-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240426 FILED AS OF DATE: 20240510 DATE AS OF CHANGE: 20240510 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DOCHERTY JOHN MARTIN CENTRAL INDEX KEY: 0001638727 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39874 FILM NUMBER: 24935519 MAIL ADDRESS: STREET 1: 23 MIKELEN DRIVE CITY: PORT PERRY STATE: A6 ZIP: L9L 1V1 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lexaria Bioscience Corp. CENTRAL INDEX KEY: 0001348362 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 202000871 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 BUSINESS ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 BUSINESS PHONE: 250-765-6424 MAIL ADDRESS: STREET 1: 100 - 740 MCCURDY ROAD CITY: KELOWNA STATE: A1 ZIP: V1X 2P7 FORMER COMPANY: FORMER CONFORMED NAME: LEXARIA CORP. DATE OF NAME CHANGE: 20080229 FORMER COMPANY: FORMER CONFORMED NAME: Lexaria Corp. DATE OF NAME CHANGE: 20051229 4 1 primary_doc.xml PRIMARY DOCUMENT X0508 4 2024-04-26 0 0001348362 Lexaria Bioscience Corp. LEXX 0001638727 DOCHERTY JOHN MARTIN 23 MIKELEN DRIVE PORT PERRY A6 L9L 1V1 ONTARIO, CANADA 1 1 0 0 President 0 common shares 54075 I Private Holding Company Stock Options 3 2020-04-23 2025-04-23 Common Shares 13334 13334 D Stock Options 3 2021-04-26 2026-04-26 Common Shares 18000 31334 D Stock Options 3 2021-06-08 2026-06-08 Common Shares 18334 49668 D Stock Options 3 2021-09-01 2026-09-01 Common Shares 15000 64668 D Stock Options 2.91 2022-08-29 2027-08-29 Common Shares 30000 94668 D Stock Options 1.15 2023-10-26 2028-10-26 Common Shares 30000 124668 D Stock Options 2.36 2024-04-26 4 A 0 49500 0 A 2024-04-26 2029-04-26 Common Shares 49500 174168 D Repriced from $9.60 pursuant to shareholder approval received on May 9, 2023 Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023 Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023 /John Docherty/ 2024-05-10